Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 12, 2006, Pages 4035-4046

  Randolph, John T ^a   Huang, Peggy P ^a   Flosi, William J ^a   DeGoey, David ^a   Klein, Larry L ^a   Yeung, Clinton M ^a   Flentge, Charles ^a   Sun, Mingua ^a   Zhao, Chen ^a   Dekhtyar, Tatyana ^a   Mo, Hongmei ^a   Colletti, Lynn ^a   Kati, Warren ^a   Marsh, Kennan C ^a   Molla, Akhteruzzaman ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Aspartyl protease inhibitors; HIV; Lopinavir resistant virus; Peptidomimetic

Indexed keywords

2 (2,4 DIOXO 3 PYRIDIN 4 YLMETHYLIMIDAZOLIDIN 1 YL) 3 METHYLBUTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL]ISOBUTYLAMINO] PROPYL]AMIDE; 2 (2,4 DIOXO 3 PYRIDIN 4 YLMETHYLIMIDAZOLIDIN 1 YL) 3 METHYLPENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL]ISOBUTYLAMINO] PROPYL]AMIDE; 3 METHYL 2 (2 OXO 3 PYRIDIN 2 YLMETHYLPYRIDIN 1 YL)PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL]ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 (2 OXO 3 PYRIDIN 3 YLMETHYLPYRIDIN 1 YL)PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL]ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 (2 OXO 3 PYRIDIN 4 YLMETHYLPYRIDIN 1 YL)PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL]ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (2 METHYLPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (2 METHYLPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 3 [CYCLOPENTYLMETHYL [4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] AMINO] 2 HYDROXYPROPYL]AMIDE; 3 METHYL 2 [3 (2,4 DIMETHYLPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (4 METHYLPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (4 METHYLPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 3 [CYCLOPENTYLMETHYL [4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] AMINO] 2 HYDROXYPROPYL]AMIDE; 3 METHYL 2 [3 (6 ISOPROPYLPYRIDIN 2 YLMETHYL) 2 OXOIMIDAZOLIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (6 METHOXYPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (6 METHYLPYRIDIN 2 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL] 3 METHYLPENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL) BENZENESULFONYL]ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (6 METHYLPYRIDIN 2 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3 METHYL 2 [3 (6 METHYLPYRIDIN 3 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]PENTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3,3 DIMETHYL 2 (2 OXO 3 PYRIDIN 3 YLMETHYLIMIDAZOLIDIN 1 YL)BUTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL]ISOBUTYLAMINO] PROPYL]AMIDE; 3,3 DIMETHYL 2 [3 (6 METHOXYMETHYLPYRIDIN 2 YLMETHYL) 2 OXOIMIDAZOLIDIN 1 YL]BUTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; 3,3 DIMETHYL 2 [3 (6 METHYLPYRIDIN 3 YLMETHYL)IMIDAZOLIDIN 1 YL]BUTANOIC ACID [1 BENZYL 2 HYDROXY 3 [[4 (HYDROXYIMINOMETHYL)BENZENESULFONYL] ISOBUTYLAMINO]PROPYL]AMIDE; ANTIVIRUS AGENT; CYTOCHROME P450 3A; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; RAT; SERUM; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; ANTI-HIV AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOGS; DRUG DESIGN; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; PYRIDINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

ANIMALIA; CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646172086     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.02.013     Document Type: Article

References (24)

1. For recent reviews covering current HIV PI therapy, see:. Randolph J.T., and DeGoey D.A. Curr. Top. Med. Chem. 4 (2004) 1079
2. Ogden R. Infect. Dis. Ther. 30 (2003) 523
3. For recent reviews on resistance to HIV protease inhibitors, see:. De Mendoza C., and Soriano V. Curr. Drug Metab. 5 (2004) 321
4. Velazquez-campoy A., Muzammil S., Ohtaka H., Schoen A., Vega S., and Freire E. Curr. Drug Targets: Infect. Disorders 3 (2003) 311
5. For recent reviews on Kaletra, see:. Cvetkovic R.S., and Goa K.L. Drugs 63 (2003) 769
6. Walmsley S., and Christian M.D. Expert Rev. Anti-infect. Ther. 1 (2003) 389
7. Corbett A.H., Lim M.L., and Kashuba A.D.M. Ann. Pharmacother. 36 (2002) 1193
8. Qazi N.A., Morlese J.F., and Pozniak A.L. Expert Opin. Pharmacother. 3 (2002) 315
9. Sham H.L., Betebenner D.A., Chen X., Saldivar A., Vasavanonda S., Kempf D.J., Plattner J.J., and Norbeck D.W. Bioorg. Med. Chem. Lett. 12 (2002) 1185
10. Stoll V., Qin W., Stewart K.D., Jakob C., Park C., Walter K., Simmer R.L., Helfrich R., Bussiere D., Kao J., Kempf D.J., Sham H.L., and Norbeck D.W. Bioorg. Med. Chem. 10 (2002) 2803
11. Yeung C.M., Klein L.L., Flentge C.A., Randolph J.T., Zhao C., Sun M., Dekhtyar T., Stoll V.S., and Kempf D.J. Bioorg. Med. Chem. Lett. 15 (2005) 2275
12. Mo H., Lu L., Dekhtyar T., Stewart K.D., Sun E., Kempf D.J., and Molla A. Antiviral Res. 59 (2003) 173
13. For an account of the initial discovery of protease inhibitors designed as salvage agents for lopinavir, which identified the utility of the arylmethyl-substituted imidazolidin-2-one P3 group, see: Flentge, C.; DeGoey, D.; Grampovnik, D.; Flosi, W.; Klein, L.; Colletti, L.; Dekhtyar, T.; Kempf, D. J. Manuscript in preparation.
14. For an account of the discovery of imidazolidin-2,4-dione containing protease inhibitors and a detailed description of methods for their synthesis, see: Flosi, W. J.; DeGoey, D. A.; Grampovnik, D. J.; Chen, H.-J.; Klein, L. L.; Dekhtyar, T.; Masse, S.; Marsh, K. C.; Mo, H.; Kempf, D. J. Manuscript in preparation.
15. Rich D.H., Sun C.-Q., Prasad J.V.N.V., Pathiasseril A., Toth M.V., Marshall G.R., Clare M., Mueller R.A., and Houseman K. J. Med. Chem. 34 (1991) 1222
16. Luly J.R., Dellaria J.F., Plattner J.J., Soderquist J.L., and Nwe Y. J. Org. Chem. 52 (1987) 1487
17. Antiviral activities were determined in MT4 cells infected with HIV-1 according to the methods described in:. Molla A., Vasavanonda S., Kumar G., Sham H.L., Johnson M., Grabowski B., Denissen J.F., Kohlbrenner W., Plattner J.J., Leonard J.M., Norbeck D.W., and Kempf D.J. Virology 250 (1998) 255
18. For methods used to evaluate pharmacokinetic properties of compounds in the presence of ritonavir, see:. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., and Leonard J.M. Antimicrob. Agents Chemother. 41 (1997) 654
19. For a recent review on the use of ritonavir to boost pharmacokinetics of protease inhibitors in combination therapy, see:. Cooper C.L., Van Heeswijk R.P.G., Galicano K., and Cameron D.W. Clin. Infect. Dis. 36 (2003) 1582
20. Kumar G.N., Dykstra J., Roberts E.M., Jayanti V.K., Hickman D., Uchic J., Yao Y., Surber B., Thomas S., and Granneman G.R. Drug Metab. Dispos. 27 (1999) 902
21. Inhibition of cytochrome P450 3A4 was determined using a variation on the reported method:. Walsky R.L., and O'Bach R.S. Drug Metab. Dispos. 32 (2004) 647
22. Cieciuch, R. F. W.; Luhowy, R. R.; Meneghini, F. A.; Rogers, H. G. U.S. Patent 4,098,783.
23. Ghosh A.K., and Fidanze S. J. Org. Chem. 63 (1998) 6146
24. Kempf D.J., Sham H.L., Marsh K.C., Flentge C.A., Betebenner D., Green B.E., McDonald E., Vasavanonda S., Saldivar A., Wideburg N.E., Kati W.M., Ruiz L., Zhao C., Fino L., Patterson J., Molla A., Plattner J.J., and Norbeck D.W. J. Med. Chem. 41 (1998) 602